Combination therapy for advanced non-small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new combination treatment (SCTB41 plus docetaxel) for people with advanced non-small cell lung cancer who have already tried other treatments. The goal is to see if this combination can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of lung cancer called non-small cell lung cancer that has spread to nearby tissues or other parts of the body and cannot be removed with surgery.
- You are able to take care of yourself (up and about, but not necessarily fully active).
- You have had certain prior treatments: If your cancer does not have certain gene changes, you must have had a type of immunotherapy and chemotherapy. If your cancer has specific gene changes, you must have had appropriate targeted therapy.
- You have not been treated with docetaxel before.
- You do not have symptoms from cancer spread to the brain.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (SCTB41) combined with chemotherapy for people with advanced squamous non-small cell lung cancer who have not had any prior treatment. It aims to see if this combination works better than standard therapy.
This trial tests a new drug combination for a type of lung cancer called squamous non-small cell lung cancer. It aims to see if the combination can help people whose cancer has grown after standard treatments.
This trial tests a new drug, SCTB14, as a first treatment for advanced non-small cell lung cancer that has a high level of PD-L1. It aims to see if the drug is safe and effective for people who haven't had other treatments for their cancer.
This trial tests two new study drugs (SCTB41 and SCTB39-1) given together, sometimes with standard treatment, to see if they are safe and effective against advanced solid tumors. If you join, you will receive these drugs and be monitored for how well they fight the cancer.
This trial tests a combination of two newer drugs (sacituzumab tirumotecan and anlotinib) for people with extensive-stage small cell lung cancer that has progressed after one prior treatment. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a new combination of two drugs for people with extensive-stage small cell lung cancer that has progressed after initial treatment. The goal is to see if this combination can help control the cancer.
Hear when a new NSCLC (Advanced Non-small Cell Lung Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.